Early Progression with Nodal Involvement Is a Predictor of Early Mortality in Mycosis Fungoides: A Retrospective, Registry-Based Cohort Study.
- 1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, 11528 Athens, Greece.
- 2Clinic & Laboratory of Pathophysiology, Department of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Abstract
Nodal involvement is a key indicator of advanced disease in mycosis fungoides (MF). While progression within 24 months is prognostic of survival in other indolent lymphomas, such clinical benchmarks in MF remain underexplored. We aimed to evaluate whether early nodal progression after the initial diagnosis serves as an independent, dynamic clinical predictor of early mortality in patients with MF. This retrospective, registry-based study utilized data from TriNetX. Evaluating post-diagnosis timepoints from 12 to 36 months, the 12-month landmark demonstrated the greatest survival divergence and was selected as the optimal threshold for early nodal progression. Patients without nodal involvement within the first 12 months served as controls. To mitigate immortal time bias, a strict 12-month landmark analysis was employed. Among 25,419 screened patients, 2132 (8.4%) developed nodal involvement within the first 12 months (NODE12). At the 12-month landmark, 21,840 patients were evaluable: 1832 with NODE12 and 20,008 controls. At this landmark, the 5-year overall survival rate was 74.8% for NODE12 patients versus 87.8% for controls (p < 0.001). In multivariable Cox regression, NODE12 was an independent predictor of early mortality (aHR = 1.97, 95% CI: 1.77-2.20, p < 0.001), alongside advanced age (aHR = 3.58, p < 0.001) and lymphocytosis (aHR = 1.69, p < 0.001). This survival disadvantage was further confirmed in the PSM sensitivity analysis of 1992 matched pairs (HR = 1.96, 95% CI: 1.66-2.31, p < 0.001). In conclusion, NODE12 is a dynamic clinical milestone identifying a high-risk MF phenotype. Similar to POD24 in B-cell lymphomas, NODE12 identifies a high-risk patient subgroup that may benefit from closer monitoring and refined risk stratification.
Related
- Pre-admission Nutritional Risk as an Independent Predictor of 28-Day Mortality After Hip Fracture: A Retrospective Cohort Study
- Systemic inflammatory response index as an independent predictor of all-cause mortality in patients receiving maintenance hemodialysis: a retrospective cohort study
- Frailty as a Predictor of Mortality in Dialysis: A Multicenter Validation of the Clinical Frailty Scale
- Analysis of Risk Factors and Development of a Predictive Model for 1-Year Mortality After Acute Hip Fracture Surgery in Patients Aged ≥80 Years: The Prognostic Nutritional Index as a Potential Predictor.
- Remnant-cholesterol-inflammatory-index as a novel predictor of cardiometabolic risk and cardiovascular mortality in elderly patients with severe aortic stenosis
BibTeX
@article{filippatos2026early,
title = {{Early Progression with Nodal Involvement Is a Predictor of Early Mortality in Mycosis Fungoides: A Retrospective, Registry-Based Cohort Study.}},
author = {Charalampos Filippatos and Despina Fotiou and Alexandros Briasoulis and Ioannis Ntanasis-Stathopoulos and Evangelos Terpos and Maria Gavriatopoulou},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
month = sep,
doi = {10.3390/curroncol33100583},
url = {https://europepmc.org/article/MED/42930150},
note = {CC BY},
}
RIS
TY - JOUR
TI - Early Progression with Nodal Involvement Is a Predictor of Early Mortality in Mycosis Fungoides: A Retrospective, Registry-Based Cohort Study.
AU - Charalampos Filippatos
AU - Despina Fotiou
AU - Alexandros Briasoulis
AU - Ioannis Ntanasis-Stathopoulos
AU - Evangelos Terpos
AU - Maria Gavriatopoulou
PY - 2026
DA - 2026/09/29
JO - Current oncology (Toronto, Ont.)
DO - 10.3390/curroncol33100583
UR - https://europepmc.org/article/MED/42930150
AB - Nodal involvement is a key indicator of advanced disease in mycosis fungoides (MF). While progression within 24 months is prognostic of survival in other indolent lymphomas, such clinical benchmarks in MF remain underexplored. We aimed to evaluate whether early nodal progression after the initial diagnosis serves as an independent, dynamic clinical predictor of early mortality in patients with MF. This retrospective, registry-based study utilized data from TriNetX. Evaluating post-diagnosis timepoints from 12 to 36 months, the 12-month landmark demonstrated the greatest survival divergence and was selected as the optimal threshold for early nodal progression. Patients without nodal involvement within the first 12 months served as controls. To mitigate immortal time bias, a strict 12-month landmark analysis was employed. Among 25,419 screened patients, 2132 (8.4%) developed nodal involvement within the first 12 months (NODE12). At the 12-month landmark, 21,840 patients were evaluable: 1832 with NODE12 and 20,008 controls. At this landmark, the 5-year overall survival rate was 74.8% for NODE12 patients versus 87.8% for controls (p < 0.001). In multivariable Cox regression, NODE12 was an independent predictor of early mortality (aHR = 1.97, 95% CI: 1.77-2.20, p < 0.001), alongside advanced age (aHR = 3.58, p < 0.001) and lymphocytosis (aHR = 1.69, p < 0.001). This survival disadvantage was further confirmed in the PSM sensitivity analysis of 1992 matched pairs (HR = 1.96, 95% CI: 1.66-2.31, p < 0.001). In conclusion, NODE12 is a dynamic clinical milestone identifying a high-risk MF phenotype. Similar to POD24 in B-cell lymphomas, NODE12 identifies a high-risk patient subgroup that may benefit from closer monitoring and refined risk stratification.
SN - 1198-0052
SN - 1718-7729
ER -